Stock AnalizViatris Inc VTRS
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Viatris Inc (VTRS) is a healthcare company listed in the US with a market value of about $23.9B. In the twelve months to September 30, 2026 it had revenue of $14.7B and net income of -$608M, a net margin of -4.1%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is shareholder returns (5/5); the weakest is track record (0/5).
Key numbers: a price to free cash flow of 11.3, 5-year revenue growth of 4% a year, a 5-year average ROIC of -1%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 51% below the current price.
Score: 1.6 / 5
Checks passed
- P/FCF below 20
- Strong R&D investment or growth above 20%
- Positive free cash flow
- Pays a dividend
- Share count down over 3 years (buybacks)
- 20% to 100% of free cash flow returned to shareholders
- Dividend 3 years in a row
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.7B | $14.3B | $14.7B | $15.4B | $16.3B | $17.9B | $11.9B | $11.5B | $11.4B |
| Net income | -$608M | -$3.5B | -$634M | $55M | $2.1B | -$1.3B | -$670M | $17M | $352M |
| Free cash flow | $2.1B | $1.9B | $2.0B | $2.5B | $2.6B | $2.6B | $989M | $1.6B | $2.1B |
| EPS (diluted) | $-0.53 | $-3.00 | $-0.53 | $0.05 | $1.71 | $-1.05 | $-1.11 | $0.03 | $0.68 |
| Net margin | -4.1% | -24.6% | -4.3% | 0.4% | 12.8% | -7.1% | -5.6% | 0.1% | 3.1% |
| ROIC | — | -8.7% | 0.0% | 1.6% | 2.9% | -0.1% | -0.4% | 4.4% | 5.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 10 analysts is $21.00, 1% above the current price; targets range from $14.00 to $28.00; the consensus rating is “Buy”; expected EPS is $2.59 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Viatris stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 51% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Viatris pay a dividend?
Yes. The dividend yield is about 2.28%, and it has paid dividends for 5 years in our data.
Is Viatris a good stock to buy?
We do not give buy or sell advice. Viatris scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.